Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer
Addition of trastuzumab modulates the immune microenvironment, suggesting the potential mechanism of the favorable outcome of anti-HER2 therapy and providing a theoretical rationale for the combinational immunotherapy in resectable HER2(+) GC patients.
Authors
- Yu Ling Sun (ORCID: https://orcid.org/0000-0003-3024-0331)
- Qian Yao (ORCID: https://orcid.org/0000-0002-4581-5989)
- Qifei He (ORCID: https://orcid.org/0000-0002-0059-9493)
- Xiaofang Xing (ORCID: https://orcid.org/0000-0002-5707-3396)
- Jing Han (ORCID: https://orcid.org/0000-0001-6490-2052)
- Zuofu Peng
- Jiafu Ji (ORCID: https://orcid.org/0000-0001-6878-5543)
- Cong Chen (ORCID: https://orcid.org/0009-0002-7322-0007)
- Xueying Wang (ORCID: https://orcid.org/0009-0003-6827-7516)
Institutions
- Peking University (CN)
- Sinovac Biotech (CN)
- Peking University Cancer Hospital (CN)
- Ministry of Education (ET)
- Shenzhen Second People's Hospital (CN)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1038/s41416-024-02835-z
- Citations
- 4
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- National Natural Science Foundation of China
- Peking University